Seagen Inc

SGEN

NASDAQ. Currency in USD

121.02 -0.37 ( -0.30% )

Real time prices: December 01

Market Cap.
22.47B
Beta (5Y monthly)
0.60
Price/Earnings
-
EPS (TTM)
-3.45
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
730,210
1y Target Est.
164.90
Day's Range
120.11
-
122.76
52 Week's Range
105.43
-
183.00

Historical Summary

Performance
EPS growth
Share Buybacks

About Seagen Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.seagen.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
182.86M
Employees
2675
Address
21823 30th Drive SE, Bothell, WA, United States, 98021
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Latest news

2 Growth Stocks to Buy if the Bear Market Continues in 2023
2 Growth Stocks to Buy if the Bear Market Continues in 2023

These stocks aren't bargain buys just yet, but they could be soon.
By The Motley Fool - 18 hours ago

Expert Ratings for Seagen
Expert Ratings for Seagen

Over the past 3 months, 12 analysts have published their opinion on Seagen (NASDAQ:SGEN) stock....
By Benzinga - 1 week ago

The Zacks Analyst Blog Highlights Merrimack Pharmaceuticals, Moderna and Seagen
The Zacks Analyst Blog Highlights Merrimack Pharmaceuticals, Moderna and Seagen

Highlights Merrimack Pharmaceuticals, Moderna and Seagen are included in this Analyst Blog.
By Zacks Investment Research - 2 weeks ago

Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More
Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More

Pipeline updates from MACK and MRNA are the key highlights from the biotech sector during...
By Zacks Investment Research - 2 weeks ago

Did You Buy And Not Sell Friday? You're Doing It Wrong - Again
Did You Buy And Not Sell Friday? You're Doing It Wrong - Again

This week saw quite a bit of volatility yet the VIX continues to fall. Read...
By Seeking Alpha - 2 weeks ago

Seagen (SGEN) Adcetris Label Expansion OK'd, New CEO Named
Seagen (SGEN) Adcetris Label Expansion OK'd, New CEO Named

The FDA approves Seagen's (SGEN) Adcetris for a new indication, treating pediatric patients with previously...
By Zacks Investment Research - 2 weeks ago

Seagen's (SGEN) Q3 Earnings Miss, Revenues Surpass Estimates
Seagen's (SGEN) Q3 Earnings Miss, Revenues Surpass Estimates

Seagen (SGEN) reports a wider-than-expected loss in the third quarter of 2022 while its revenues...
By Zacks Investment Research - 4 weeks ago

Seagen Inc. (SGEN) Q3 2022 Earnings Call Transcript
Seagen Inc. (SGEN) Q3 2022 Earnings Call Transcript

SGEN earnings call for the period ending September 30, 2022.
By The Motley Fool - 5 weeks ago